|By Marketwire .||
|October 8, 2012 09:10 AM EDT||
LAS VEGAS, NV -- (Marketwire) -- 10/08/12 -- Compass Biotechnologies Inc. (PINKSHEETS: COBI) and 1World Direct US Inc., ("1World") - The "unbanked" and financially underserved population is making its mark in the economy within a market segment that now exceeds $10 billion. "This activity only provides a glimpse of the growing and largely unmet financial needs of this customer segment and its market potential for banks and financial services providers," said Tom Krucker, CEO of 1World. Furthermore, "both new and established providers are scrambling to understand the right mix of products for this market segment as well as payment products and the delivery method or combination of methods needed to successfully reach this customer base."
1World has developed successful sales strategies to penetrate this market segment through a deep understanding of its financial needs and also of its cultural concerns. By using just a smart phone and our developed mobile apps for Android and iPhone, cardholders will have access to meet a complete range of personal banking needs; such as: activating a new account, signing up for direct deposit or ACH transfers, redeeming cash back points, paying bills, transferring funds and more.
ABOUT: 1World Direct Inc. and Compass Biotechnologies Inc.
1World Direct US Inc., a wholly owned subsidiary of Compass Biotechnologies Inc. (PINKSHEETS: COBI), integrates and provides direct payment systems into the global community that positions the company above its direct competition. 1World Direct US leverages the integration of its branded cards and expands access to its stored value cards for consumers through multiple distribution channels. 1World Direct US provides a singular competitive resource for affordable funds transfer and stored value products and services generating continued profits for its shareholders.
Certain statements in this release, other than statements of historical fact, may include forward-looking information that involves various risks and uncertainties. There can be no assurance that such forward-looking statements will prove to be accurate. Actual result and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change, other than as required pursuant to applicable securities laws.
Compass Biotechnologies Inc.